Robert S. Laitman, MD, discusses evidence supporting the reclassification of schizophrenia as a neurological disorder, his views on how reclassification could impact prognosis and recovery, and treatment interventions he says have led to...
Robert S. Laitman, MD, discusses evidence supporting the reclassification of schizophrenia as a neurological disorder, his views on how reclassification could impact prognosis and recovery, and treatment interventions he says have led to...
In this podcast, Matthew Robbins, MD, overviews the treatments for migraine that are currently available, assesses the risks and benefits of using each treatment in clinical practice, and explains how to use some of these treatments in...
In this podcast, Matthew Robbins, MD, overviews the treatments for migraine that are currently available, assesses the risks and benefits of using each treatment in clinical practice, and explains how to use some of these treatments in...
In this podcast, Shane Liddelow, PhD, from NYU Langone Health, discusses his latest research on astrocytes—a topic he also spoke about at the Alzheimer's Association International Conference 2019.
In this podcast, Shane Liddelow, PhD, from NYU Langone Health, discusses his latest research on astrocytes—a topic he also spoke about at the Alzheimer's Association International Conference 2019.
In this podcast, Amita Sehgal, PhD, talks about using small-animal models, such as fruit fly models, to determine how and why we sleep. Do flies actually sleep? Listen in to find out!
In this podcast, Amita Sehgal, PhD, talks about using small-animal models, such as fruit fly models, to determine how and why we sleep. Do flies actually sleep? Listen in to find out!
Hesham Abboud, MD, PhD, talks about his research on movement disorders in patients with multiple sclerosis, what the results mean for clinicians, and more.
Hesham Abboud, MD, PhD, talks about his research on movement disorders in patients with multiple sclerosis, what the results mean for clinicians, and more.
In this podcast, Mary A. O'Neal, MD, from Brigham and Women's Hospital, talks about hormones and migraine, the research gaps that need to be filled, and the lessons we have learned about migraine so far.
In this podcast, Mary A. O'Neal, MD, from Brigham and Women's Hospital, talks about hormones and migraine, the research gaps that need to be filled, and the lessons we have learned about migraine so far.
Diane Lipscombe, PhD, and Christopher Moore, PhD, from Brown University, discuss their bioluminescence project, how it can affect neurological therapies in the future, and how you can be part of their ongoing research.
Diane Lipscombe, PhD, and Christopher Moore, PhD, from Brown University, discuss their bioluminescence project, how it can affect neurological therapies in the future, and how you can be part of their ongoing research.
In patients with acute ischemic stroke eligible for intravenous thrombolysis within 4.5 hours of symptom onset, tenecteplase was noninferior to alteplase for achieving an excellent functional outcome at day 90.
In patients with acute ischemic stroke eligible for intravenous thrombolysis within 4.5 hours of symptom onset, tenecteplase was noninferior to alteplase for achieving an excellent functional outcome at day 90.
Intravenous Lu AG09222 reduced migraine frequency over 4 weeks in patients who had failed to find relief with previous treatments, according to a phase 2 trial published in the New England Journal of Medicine.
Intravenous Lu AG09222 reduced migraine frequency over 4 weeks in patients who had failed to find relief with previous treatments, according to a phase 2 trial published in the New England Journal of Medicine.
Patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping demonstrated unprecedented dystrophin expression and functional improvement with the investigational therapeutic DYNE-251.
Patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping demonstrated unprecedented dystrophin expression and functional improvement with the investigational therapeutic DYNE-251.
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Patients with MS had about half the rate of amyloid pathology compared with matched control subjects in the Washington University School of Medicine study.
Patients with MS had about half the rate of amyloid pathology compared with matched control subjects in the Washington University School of Medicine study.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
A new cohort study involving female participants found no link between migraine and later Parkinson disease (PD) development. Findings from the study were published in Neurology.
A new cohort study involving female participants found no link between migraine and later Parkinson disease (PD) development. Findings from the study were published in Neurology.
As millions of Americans, both children and adult, prepare to return to school next week, an ongoing challenge has once again reared its head: a shortage of stimulant drugs used to treat attention-deficit/hyperactivity disorder (ADHD).
As millions of Americans, both children and adult, prepare to return to school next week, an ongoing challenge has once again reared its head: a shortage of stimulant drugs used to treat attention-deficit/hyperactivity disorder (ADHD).
The risk of developing Parkinson disease (PD) is doubled in adults 50 and older with new-onset anxiety compared with those without anxiety, according to a study published in the British Journal of General Practice.
The risk of developing Parkinson disease (PD) is doubled in adults 50 and older with new-onset anxiety compared with those without anxiety, according to a study published in the British Journal of General Practice.
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click